280E Is Dead for Medical Cannabis: How Schedule III Saves Millions

For over a decade, Section 280E of the Internal Revenue Code has been the single most destructive force in legal cannabis business. A provision originally designed in 1982 to prevent drug traffickers from deducting business expenses on their tax returns has been applied with brutal efficiency to state-licensed, fully legal cannabis companies — forcing them to pay effective tax rates as high as 70 percent while competing against a black market that pays nothing.

On April 22, 2026, that era began to end. The Department of Justice formally reclassified certain categories of cannabis from Schedule I to Schedule III of the Controlled Substances Act, and with that single administrative action, the 280E tax nightmare started to lift for a significant portion of the legal cannabis industry.

What 280E Actually Did

To understand the magnitude of this change, you need to understand how absurd 280E was in practice.

Under normal tax law, every business in America — from restaurants to tech startups to oil companies — deducts its ordinary operating expenses before calculating taxable income. Rent, payroll, utilities, marketing, insurance, interest on loans — these are all standard deductions that reduce a company's tax burden to a reasonable level.

Section 280E stripped cannabis companies of all of those deductions. The only expense they could claim was the direct cost of goods sold — essentially the cost of growing or purchasing the cannabis itself. Everything else — the dispensary lease, the budtenders' salaries, the compliance software, the security systems, the accounting fees — was paid entirely with after-tax dollars.

The result was devastating. A cannabis company generating $5 million in revenue with $3 million in operating expenses didn't pay taxes on $2 million in profit. It paid taxes on nearly the full $5 million, minus only the cost of the product itself. Companies that were barely profitable on paper faced tax bills that consumed most of their actual cash flow.

What Changed on April 22

The DOJ's rescheduling order moved two categories of cannabis to Schedule III. The first category includes FDA-approved drug products containing marijuana, such as Epidiolex. The second — and far more commercially significant — category covers marijuana products manufactured, distributed, or dispensed under a qualifying state-issued medical cannabis license.

Because Section 280E only applies to businesses trafficking in Schedule I or Schedule II controlled substances, moving medical cannabis to Schedule III immediately exempts state-licensed medical marijuana operators from the provision. Starting with tax year 2026, these businesses can deduct their full range of ordinary business expenses just like any other legal enterprise.

The deductions that become available include payroll and employee benefits, facility rent and lease payments, marketing and advertising costs, professional services like legal and accounting, insurance premiums, equipment depreciation, and interest on business loans.

Who Benefits — and Who Doesn't

The relief is significant but not universal. The rescheduling order specifically covers cannabis products subject to a state-issued medical marijuana license. Adult-use or "recreational" cannabis remains classified under Schedule I and continues to be subject to 280E.

This creates a bifurcated landscape. In states with both medical and adult-use programs, operators with medical licenses can deduct expenses attributable to their medical cannabis operations while still facing 280E restrictions on their recreational sales. The accounting complexity is real, but the financial relief is substantial.

For the twelve largest multi-state operators (MSOs), a 2023 analysis by Viridian Capital Advisors estimated that full elimination of 280E restrictions could save a combined $700 million or more annually in federal taxes. Even partial relief — applying only to medical operations — represents hundreds of millions in aggregate savings across the industry.

Industry-wide, analysts project that the Schedule III reclassification could generate over $2 billion in additional cash flow for the legal cannabis sector, money that has been flowing to the IRS instead of being reinvested in operations, expansion, and compliance.

The IRS and Retroactive Relief

The rescheduling order goes further than prospective tax relief. It directs the IRS to consider providing retrospective relief from 280E liability for prior taxable years in which a state-licensed medical cannabis operator was subject to the provision.

If the IRS follows through, some cannabis companies could receive refunds or credits for taxes paid under 280E in previous years. The potential retroactive relief is particularly significant for operators who have been in business for many years and have accumulated substantial 280E tax liabilities.

However, the scope and mechanics of any retroactive relief remain uncertain. The IRS has not yet issued formal guidance on how retrospective claims would be evaluated, what documentation would be required, or how far back the relief period would extend. Cannabis tax attorneys are advising clients to preserve all historical records in anticipation of future guidance.

What This Means for Cannabis Stocks

The financial markets have already begun pricing in the impact of 280E relief. Cannabis equities, particularly shares of large MSOs with significant medical operations, have seen renewed investor interest in 2026. The AdvisorShares Pure US Cannabis ETF (MSOS) has shown positive momentum, and individual operators like Trulieve and Curaleaf — both of which have large medical cannabis footprints — are among the most closely watched beneficiaries.

Verano Holdings recently approved a 1-for-5 reverse stock split as it positions for a potential listing on a major U.S. stock exchange. The improved financial profile that 280E relief enables makes such listings more feasible, as companies can now present financial statements that reflect actual profitability rather than artificially inflated tax burdens.

Cannabis stocks also began trading on the Robinhood brokerage platform in 2026, increasing retail investor access to the sector and adding a new source of potential demand for cannabis equities.

The Unfinished Business

While the April 22 rescheduling order provides real relief, it leaves significant work undone. The broader question of whether all marijuana — including adult-use cannabis — should be moved to Schedule III is the subject of a DEA administrative hearing scheduled to begin on June 29, 2026.

If that hearing ultimately results in comprehensive rescheduling, 280E would cease to apply to the entire legal cannabis industry, not just medical operators. The financial impact would be transformative, potentially doubling or tripling the cash flow of adult-use operators who currently bear the full weight of the provision.

The hearing also faces legal challenges. Prohibitionist organizations have filed lawsuits seeking to reverse the DOJ's rescheduling order entirely, arguing that the administrative process was improper. The outcome of these challenges could determine whether even the current medical-only relief survives.

The Competitive Landscape Shifts

The elimination of 280E for medical cannabis changes the competitive dynamics of the industry in several ways. Companies with larger medical footprints gain a disproportionate advantage, as a greater share of their revenue becomes subject to normal tax treatment. This could accelerate consolidation, as well-capitalized operators with strong medical programs acquire smaller competitors still struggling under 280E's burden on their recreational operations.

States considering adult-use legalization may also find new urgency to act. If adult-use cannabis eventually moves to Schedule III, companies already operating in those markets will benefit immediately. States that delay legalization risk missing the window when 280E relief and market expansion align to create maximum growth.

The Bottom Line

The death of 280E for medical cannabis is the most significant financial event in the legal cannabis industry's history. For years, the provision functioned as a silent killer — invisible to consumers but devastating to operators. Companies that survived the 280E era did so despite the tax code, not because of it.

The relief arriving in 2026 won't solve every problem facing the cannabis industry. Regulatory fragmentation, banking limitations, and the persistent black market remain formidable challenges. But for the first time, state-licensed medical cannabis businesses can operate under tax rules that treat them like what they are: legal enterprises providing products that millions of Americans use every day.

That's not just a tax break. It's a recognition, however partial, that the war on cannabis businesses through the tax code is finally coming to an end.